Recently, studies on osteosarcoma cells have shown that the combined use of other ferroptosis inducers (such as erastin and RSL3) or STAT3 inhibitors can enhance the sensitivity of cells to cisplatin, providing a new idea for the treatment of drug-resistant osteosarcoma 130. Here, STAT3 is linked to osteosarcoma.